Research chair named after Dr. Salem

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 9
Volume 19
Issue 9

St. Luke’s Episcopal Hospital has established the Philip A. Salem, MD, Chair in Cancer Research.


PHILIP A. SALEM, MD

St. Luke's Episcopal Hospital has established the Philip A. Salem, MD, Chair in Cancer Research. This is the first chair in cancer research established at the Houston-based hospital which is part of the Texas Medical Center.

Dr. Salem is the director of the cancer research program at St. Luke's. His groundbreaking work in chemoprevention, including the link between chronic gastrointestinal infections and the risk of cancer, has led to research focusing on isolating and treating precancerous infections.

Recent Videos
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
Alessio Pigazzi, MD, PhD, FACS, FASCRS, provides advice for upcoming surgeons starting out in the colorectal cancer field.
Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed how robot-assisted surgery for colorectal cancers has evolved over the past 20 years.
Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed surgical and medical oncology developments in the colorectal cancer field.
4 KOLs are featured in this panel.
Related Content